Hostname: page-component-7b7567c8c-lpg2g Total loading time: 0 Render date: 2026-11-15T21:27:21.284Z Has data issue: false hasContentIssue false

Evaluating racial and ethnic disparities in antibiotic treatment for pneumonia patients in a major academic health system

Published online by Cambridge University Press:  20 December 2024

David Evans
Affiliation:
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA
Kingsley Fortin-Leung
Affiliation:
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Vishnu Ravi Kumar
Affiliation:
Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA
Yanru Ma
Affiliation:
Department of Biostatistics and Bioinformatics, Emory University Rollins School of Public Health, Atlanta, GA, USA
Radhika Prakash Asrani
Affiliation:
Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA
Zanthia Wiley
Affiliation:
Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA
Scott K. Fridkin*
Affiliation:
Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, GA, USA
*
Corresponding author: Scott K. Fridkin; Email: sfridki@emory.edu

Abstract

Objective:

Examine the relationship between patients’ race and prescriber antibiotic choice while accounting for differences in underlying illness and infection severity.

Design:

Retrospective cohort analysis.

Setting:

Acute care facilities within an academic healthcare system.

Patients:

Adult inpatients from January 2019 through June 2022 discharged from the Hospital Medicine Service with an ICD-10 Code for Pneumonia.

Methods:

We describe variability in days of therapy of antimicrobials with activity against Pseudomonas aeruginosa (anti-Pseudomonas agents) or against MRSA (anti-MRSA agents), by patient’s race and ethnicity. We estimated the likelihood of receipt of any anti-Pseudomonas agents by race and modeled the effect of race on rate of use, adjusting for age, severity, and indication.

Results:

5,820 patients with 6,700 encounters were included. After adjusting for broad indication, severity, underlying illness, and age, use of anti-Pseudomonas agents were less likely among non-Hispanic Black patients than other race groups, although this effect was limited to younger patients (adjusted odds ratio [aOR] 0.45, 95% confidence interval [CI] 0.29, 0.70), and not older ones (aOR 0.98; 95% CI 0.85, 1.13); use of anti-MRSA agents were similar between groups. Among patients receiving any anti-Pseudomonas agents, Black patients received them for relatively lower proportion of their inpatient stay (incidence rate ratio 0.91; 95% CI 0.87, 0.96).

Conclusions:

We found difference in use of anti-Pseudomonas agents between non-Hispanic Black patients and other patients that could not be easily explained by indications or underlying illness, suggesting unmeasured factors may be playing a role in treatment decisions.

Information

Type
Original Article
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America
Figure 0

Table 1.Characteristics of Inpatient Encounters of Pneumonia Hospitalizations and Discharged by Hospital Medicine Service, by Race & Ethnicity, Emory Healthcare, January 1, 2019, to June 30, 2022

Figure 1

Table 2.Multivariate model estimating independent effect of patient or illness characteristic on receipt of any day of therapy of the anti-pseudomonas agents, or anti-MRSA agents during 6700 inpatient hospitalizations with Pneumonia among 5820 patients

Supplementary material: File

Evans et al. supplementary material

Evans et al. supplementary material
Download Evans et al. supplementary material(File)
File 56.3 KB